argenx to Present at 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
argenx (Euronext & Nasdaq: ARGX) announced that CEO Tim Van Hauwermeiren will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT.
A live webcast will be available on the company's Investors website at argenx.com/investors, and a replay will be accessible on the site for approximately 30 days after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ARGX gained 0.36%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ARGX is down 4.66% while key biotech peers show smaller moves: REGN -0.84%, INSM -0.52%, ONC -0.68%, VRTX -0.01%, ALNY +0.07%, suggesting a more stock-specific move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 15 | Clinical trial update | Negative | -3.1% | Phase 3 UplighTED studies discontinued after futility recommendation. |
| Nov 18 | Governance update | Positive | -0.4% | Extraordinary meeting approved new remuneration policy with strong support. |
| Oct 30 | Earnings & update | Positive | -0.2% | Reported strong Q3 2025 results and reaffirmed R&D and SG&A guidance. |
| Oct 29 | Clinical data update | Positive | -1.7% | New VYVGART data showed efficacy and favorable safety in myasthenia gravis. |
| Oct 23 | Earnings preview | Neutral | -0.2% | Announcement of timing and access details for Q3 2025 results call. |
Recent news often saw negative price reactions, including on positive clinical, financial, and governance updates, indicating a pattern of weak or skeptical responses to announcements.
Over the last few months, argenx has reported mixed developments. On Oct 30, 2025, strong Q3 results with $1.13 billion in net product sales and $4.3 billion in cash still coincided with a slight share decline. Positive VYVGART data and favorable remuneration vote outcomes in late 2025 also saw mild negative reactions. The December 2025 discontinuation of the UplighTED TED studies for futility drew a larger drop. Today’s conference appearance fits within a cadence of frequent corporate updates.
Market Pulse Summary
This announcement highlights argenx’s planned participation at a major healthcare conference, providing a platform for management to communicate strategy and pipeline priorities. Recent history includes robust Q3 2025 results, with net product sales of $1.13 billion, alongside the setback of discontinuing the UplighTED TED studies for futility. Investors may focus on how upcoming presentations frame these mixed developments and outline the next clinical and commercial milestones to monitor.
AI-generated analysis. Not financial advice.
January 6, 2026
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT.
A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
For further information, please contact:
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
FAQ
When will argenx (ARGX) present at the J.P. Morgan Healthcare Conference in 2026?
Who from argenx (ARGX) is presenting at the January 2026 J.P. Morgan conference?
How can investors watch argenx (ARGX) presentation on January 12, 2026?
Will there be a replay of the argenx (ARGX) J.P. Morgan presentation and for how long?
What stock tickers represent argenx for investors checking the January 2026 presentation?
Where on the argenx website will the January 12, 2026 webcast be hosted?
